Arpe-19 as a platform cell line for encapsulated cell-based delivery
CA 2365532 C · Owner: Stabila, Paul F. · Inventors: Rein, David H.; Dean, Brenda, J.; Goddard, Moses B. I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions such as in central , nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; has a long life span; is of human origin; has goodin vivo device viability; delivers efficacious quantity of growth factor; triggers no or low level host immune reaction and is non-tumorigenic.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 6, 2000 and granted November 6, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 6, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 6, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.